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THE ACCURACY OF PROSTATE BIOPSY TO ASSIGN PATIENTS WITH 
LOW-GRADE PROSTATE CANCER TO ACTIVE SURVEILLANCE 
 
INTISAR GHLEILIB 
 
ABSTRACT 
Purpose: To determine the accuracy of prostate biopsy Gleason score (GS) compared to 
prostatectomy GS. To determine whether a biopsy is a satisfactory diagnostic procedure 
to offer active surveillance for patients with low-grade prostate cancer. 
Methods: This study was conducted in Tuft Medical Center as retrospective cohort study 
over the period from 2007-2010.  The study included 83 patients for whom biopsy and 
prostatectomy GS were available.    
Measurements: Gleason scores of 6, 7, and 8-10 were assigned to low, moderate, and 
high-grades, respectively. The kappa statistic was calculated to assess the degree of 
agreement between biopsy and prostatectomy. The ROC curve was used to evaluate the 
sensitivity and specificity of prostate biopsy for different Gleason grades.  
Also, compared whether the use of specific criteria for active surveillance (Johns 
Hopkins and UCSF) may decrease the level of up-grading in patient with low-grade 
prostate cancer using Chi-square test. 
Results: The distribution of low, moderate, and high-grade cancer in biopsy (52%, 32%, 
16%) and prostatectomy specimen (33%, 55%, 12%) showed fair agreement with 
weighted kappa 0.35. The prostate biopsy accurately predicted GS in 46%, up-graded in 
  vi 
38%, and down-graded in 16%. The patients with low-grade cancer and potentially 
eligible for active surveillance showed up-grading in 50% of cases. This up-grading 
reduced to 40% with the use of Johns Hopkins criteria and to 41% with the use of UCSF 
criteria. 
Conclusions: The accuracy of biopsy GS in predicting prostatectomy GS is severely 
limited and therefore biopsy is not enough diagnostic procedure to offer active 
surveillance. 
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Background 
 
1.1 Prevalence and Risk Factors of Prostate Cancer:  
Prostate cancer (PC) is the second common diagnosed cancer in men in United States. It 
is surpassed only by cutaneous cancers. It also is the second leading cause of death in 
men after lung cancer.1 According to the American Cancer Society statistics from 2013, 
238,590 new cases of prostate cancers were diagnosed, with an expected death of 
29,720.2  
 
PC is usually a disease of men of old age, with 66 being the average age of diagnosis in 
United States.3 It is rare for PC to be diagnosed before the age of 50, accounting for only 
2% of total PC cases.4 The prevalence of prostate cancer in autopsy studies range from 
one-third of men who were older than 60 to 50% of men who were older than 70.5 
 
The prevalence of prostate cancer varies between countries likely because of the 
influence of genetics, diet, and environmental factors.6 Additionally, the rate of PC is 
different between ethnic populations with the highest prevalence occurring among the 
African American population and the lowest in the Asian Chinese. 7  
 
1.2 Anatomy of the Prostate Gland: 
Anatomically, the prostate gland is part of male reproductive system situated below the 
bladder, in front of the rectum. It encircles the prostatic urethra and is covered with a 
fibrous capsule with varying degrees of thickness between different parts of the prostate 
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gland. This capsule is covered with multi-layers of complex fascia that contain fat mixed 
with areolar connective tissue, arteries, veins, nerve trunks, autonomic ganglia, and 
neural plexus.8  
 
The prostate is divided anatomically into 3 zones (Figure 1): central, peripheral, and 
transitional. For young men, the peripheral zone forms 70% of glandular prostatic tissue.9 
The central zone forms approximately 25% of the glandular prostatic tissue, with the 
remaining 5% forming the transitional zone.10 For old men, the central and transitional 
zones may expand due to benign prostatic hyperplasia.11 The peripheral zone is the main 
site of origin for prostatic carcinoma.9   
 
 
 
Figure 1: Zonal Anatomy of Prostate (sagittal plane and corresponding axial 
sections of (1) Base, (2) Middle, and (3) Apex. The 3 Prostatic Zones are: 
Transitional (blue), Central (yellow), and Peripheral (pink).12 
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1.3 Symptoms of Prostate Cancer: 
PC is a slow growing disease with a long latency period, making it a good candidate for 
screening.13 Due to the screening in the United States, 90% of men diagnosed with 
prostate cancer are asymptomatic, with their disease confined to the prostate gland 
(localized prostate cancer).14  However, as the PC becomes larger, it may cause 
symptoms such as urinary obstruction symptoms including difficulty in starting and 
stopping urination, frequent urination (in both day and night time), blood in the urine 
(hematuria), pain during urination, or a weak urine stream. 15 
 
 Advanced prostate cancer may cause other symptoms resulting from the spread of cancer 
to other tissues such as bone pain if the cancer has been spread to the bone. When the 
metastatic cancer compresses on the spinal cord, the patient may complain of weakness 
or numbness in the legs, and/or loss of bladder or rectal control.  Weight loss and fatigue 
are other presentations of advanced prostate cancer that may ultimately result in patient 
death. 15 
  
1.4 Screening and Diagnosis of Prostate Cancer: 
PC is usually diagnosed during screening procedures.16 Screening is defined as any 
procedure that is designed to diagnose the disease before it becomes symptomatic.17 
During PC screening, the blood level of prostate specific antigen (PSA) is measured 
because it is an indicator of the potential presence of PC.17 Also, a digital rectal 
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examination (DRE) is another screening method because the presence of nodules or 
hardness of the prostate gland is an indicator of  PC .13   
 
Over the past 20 years, screening for PC depended on the laboratory measurement of 
blood PSA levels.18 This marker is considered a nonspecific cancer marker because it 
also increases in benign disease like benign prostatic hypertrophy or prostatitis, or even 
with urethral manipulation.13 Thus, the challenge with using these screening methods 
(PSA level and DRE) is that they are unable to differentiate benign prostatic disease from 
PC.  Therefore, the final diagnosis of PC requires a pathological examination of prostatic 
tissues obtained by prostate biopsy.19  
 
Prostate biopsy is recommended in the patient with abnormal DRE findings regardless of 
PSA level.20  For PSA levels, there is no safe blood PSA levels below which a man can 
be assured that no cancer is present.20   However, a PSA serum concentration ≥ 4 ng/ml is 
commonly considered an abnormal test result (even with a normal DRE) that requires 
further investigation.21 The patients whose blood PSA levels range between 4-10 ng/ml 
represent a potentially high-risk group (diagnostic gray zone) who may have PC or 
benign prostatic diseases. Patients with a PSA levels >10 ng/ml are considered at high 
risk for PC, and such a test result  requires further investigation.22 
 
The indication to proceed to prostate biopsy as the next step for PC diagnosis is based 
primarily on the PSA level and DRE finding, however, it should include different factors 
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including prostate size, rate of increase in PSA, age, family history of PC, ethnicity, 
comorbidity, and previous biopsy history.23  
 
In the United States, screening methods (mainly PSA screenings) have led to the 
detection of the PC 10 years earlier than men diagnosed without screening.24 Now, nearly 
75% of patients diagnosed with PC have non-palpable tumors, with only 5% having 
advanced disease with the distal spread of tumors at the time of diagnosis. 25  
 
In clinical practice, the trans-rectal ultrasound (TRUS), a guided prostate needle biopsy is 
the gold standard for histological diagnosis of PC.26 Prostate biopsy is an out-patient, 
quick procedure that only requires local anesthesia to avoid pain and discomfort.27 When 
first introduced, TRUS-guided needle biopsies are performed according the sextant 
procedure, through which biopsy cores were taken from 6 regions of the prostate gland, 
including the bilateral base, mid-gland, and apex regions.28,29 However, the sextant 
pattern TRUS-guided needle biopsy tends to have a high false-negative rate (for missed 
cancer). For this reason and since 1990, clinicians extended the biopsy to include at least 
10-14 cores to increase the rate of cancer detection (extended biopsy see the Figure 2), 
thereby increasing the cancer detection rate to 30%.30, 31 The additional cores are usually 
taken from the lateral parts of the gland, however, it should be noted that there are no 
universal procedures for obtaining prostate biopsies.7  
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Figure 2: Standard 12 Cores Sampling Pattern for Prostate Biopsy. 
(From Dr. Gaston library. Permission was granted) 
 
Patients who have a cancer negative biopsy and who experience a continued increasing of 
PSA levels are often recommended for a repeat biopsy. The adequacy of prior biopsy is 
determined by evaluating the location and number of cores taken in relation to the 
prostate volume.31 The detection rate of repeated biopsy vary according to the number of 
cores taken in the prior biopsy.32 If the previous negative biopsy involved a sextant 
biopsy, the cancer detection rate with repeated biopsy would be 39%. While if the 
previous negative biopsy was an extended biopsy, the cancer detection rate with repeated 
biopsy would be 29%.31  
 
In some centers, saturation biopsy may be performed in patients if the risk of missing PC 
is high (e.g. increasing PSA level despite negative repeated biopsies). The number of 
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cores taking during the saturation biopsy is up to 32 cores.33 Saturation biopsy is more 
painful than extended biopsy and relatively few patients undergo this procedure .33  
 
Because in the PSA screening population, most patients are diagnosed before the tumor 
becomes palpable or visible by clinical imaging, the prostate biopsy sampling procedure 
is a systematic sampling of the gland, not the targeted lesion.26 This lesion-blind biopsy 
approach tend to miss 30% of PCs. In addition, because of the anatomical orientation of 
the prostate gland, the tumors in the anterior region of the gland tend to be 
underdiagnosed,34 oftentimes resulting in the incorrect management of the disease.35 
 
1.4.1 Grading of Prostate Cancer: 
Histological examination of biopsy tissue is the only way to confirm the diagnosis of PC  
and is necessary to assign the patient to appropriate treatment.36 The histology of normal 
prostate tissue consists of normal epithelial cells in a glandular design resting on the 
continuous supportive basal cells, embedded in connective tissue stroma. When the 
abnormal epithelial proliferation disrupts the basal layer partially, it is called prostatic 
intra-epithelial neoplasia (PIN). If these abnormal epithelial cells acquire malignant 
characteristics and the basal layer is completely lost, it is indicative of PC and a Gleason 
score is used to describe the epithelial glandular architecture.37 
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1.4.2 Gleason Score:  
The Gleason scoring system is the most widely accepted grading system to assess PC.38 
Biopsy Gleason scores are important in assigning the correct treatment for the patient 
with localized PC.39 A Gleason score is assigned after microscopic evaluation of the 
prostatic tissue received by a pathologist, either after the biopsy or surgical removal of 
the prostate (radical prostatectomy).40 
 
The Gleason grading system is different from any other grading system used for solid 
cancers. Most grading systems assess the morphology of individual cells. However, the 
Gleason system examines the glandular architecture and the cells’ relationship without 
assessing the morphology of each cell.37  
 
A Gleason grade is assigned according to the histological arrangement of tumor cells. 
This grade is determined based on the defined patterns of tissue architecture in a range of 
1 to 5. In the original Gleason grading system a pattern of 1would be assigned if the 
tumor cells closely resembled normal glandular cells (well differentiated) whereas a 
pattern of 5 would be assigned if the tumor cells were absent of any glandular pattern 
(poorly differentiated); with, grades 2- 4 lying in between (Table 1). In current practice, 
Gleason pattern 3 is the lowest grade routinely reported.41   
 
 
 
  
9 
 
Table 1: Gleason Grade Patterns of prostate cancer.41 
Gleason grade 
pattern 
Tissue characteristics 
Grade pattern 1 Single round closely packed glands arranged in nodule. 
Grade pattern 2 Variable glands shape with more stroma separating them. 
Grade pattern 3 Still recognizing glands with some cells are separating and start to 
invade surrounding tissue. 
Grade pattern 4 Few glands with more cells are separating and invade surrounding 
tissue. 
Grade pattern 5 Sheet of cells with no or few recognizing gland. 
 
Each tumor is described by its two most prevalent Gleason grade patterns. The primary 
Gleason grade pattern is the predominant pattern in the area while the secondary Gleason 
grade pattern is the second most prevalent pattern. The summation of those primary and 
secondary Gleason grade patterns results in Gleason score sums that ranges from 2-10 
(1+1 to 5+5).41 Gleason scores sums of 6-10 are the most common finding at the time of 
PC diagnosis.42  In some cases, small parts of the cancer have higher Gleason grade 
pattern compared to the 2 dominant Gleason grade patterns, resulting in a minor Gleason 
grade pattern referred to as a tertiary tumor grade pattern (e.g. Gleason score sums 7 
(pattern 3+ pattern 4, tertiary pattern 5)), as this tertiary higher Gleason grade pattern may 
change the treatment options.42   
 
 A Gleason score sum of 6 (pattern 3 + pattern 3) is indicative of low risk in terms of 
cancer progression and mortality.43 The widespread use of the PC screening in the United 
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States has led to detection of more low risk PC .41 A Gleason score sum of 7 is generally 
considered intermediate risk. However, a Gleason sum of 7 may be either predominantly 
pattern 3 (pattern 3 + pattern 4) or predominantly pattern 4 (pattern 4 + pattern 3). 
Published studies show that men with a Gleason sum of 7 (4+3) PC are more likely to 
show PC progression than Gleason sum 7 (3+4). A Gleason score sum of 8 or greater 
indicates a high-risk prostate cancer. Thus, the accurate assessment of Gleason grade is 
critical to appropriate management of patients with newly diagnosed PC.44  
 
1.5 Staging of Prostate Cancer: 
 The extent of the PC is determined by the anatomic extension of the cancer. The TNM 
system (T for the primary tumor, N for the regional lymph node involvement with the 
cancer, and M for the distal spread of cancer or metastasis) is the most common staging 
system used for prostate cancer. The correct staging is important in the prognostic 
assessment and treatment planning of patients with PC (Table 2).45  
  
Table 2:  Staging of Prostate Cancer.46 
Tumor stage Description 
T1 Tumor is not palpable. 
  
      T1a Incidental histological finding ≤5% of tissue resected. 
  
      T1b Incidental histological finding > 5% of tissue resected. 
  
      T1c Tumor identified by biopsy as a result of elevation of PSA. 
  
T2 Tumor confined within the prostate but not palpable. 
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      T2a Tumor presents in half of a single lobe or less. 
  
      T2b Tumor presents in more than half  of a single lobe but not both lobes 
  
      T2c Tumor involves both lobes 
  
T3 Tumor extends beyond prostatic capsule. 
  
      T3a Extra-capsular extension. 
  
      T3b Tumor extends to seminal vesicle(s). 
  
T4 Tumor fixed or involves other surrounding tissue other than seminal 
vesicles. 
  
      Nx Regional lymph nodes cannot be evaluated 
  
      N0  Lymph nodes are free of cancer. 
  
      N1  Lymph nodes are positive for the cancer. 
  
     Mx Distant spread of the cancer (metastasis) cannot be evaluated. 
  
     M0 The tumor does not have distant spread. 
  
     M1 The tumor has been spread distally. 
 
1.6 Risk stratification of prostatic cancer patient:  
The prognosis of PC is dependent upon the risk of disease progression, recurrence, and 
metastasis. D’ Amico et al. proposed on of the first widely recognized systems for risk 
stratification. This scheme depended on prognostic factors, including initial PSA level, 
cancer stage, Gleason score, along with other considerations such as patient age, 
comorbidity, and basal urinary function. These factors are important because treatment 
options available to treat PC are dependent upon the prognostic factors at the time of 
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diagnosis.47,48 The following risk stratification has been recommended by the NCCN 
(National Comprehensive Cancer Network) in their publication of 2012 (Table 3).49 
 
Table 3: NCCN Risk Stratification for Men with Localized Prostate Cancer.49 
  
Risk stratification PSA level (ng/ml) Gleason score Clinical stage 
Very low risk 
Low risk  
Intermediate risk  
High risk  
<10* 
<10 
10- 20 
≥ 20 
And ≤ 6** 
And ≤ 6 
Or 7 
Or 8-10 
And T1-T2a 
And T1- T2a 
Or T2b- T2c 
Or T3a  
* And PSA density < 0.15 ng/ml/g. PSA density is defined as serum PSA in ng/ml 
divided by prostate size in grams.**and < 3 positive cores with cancer and < 50% of 
cancer in any cores. 
 
 
1.7 Localized Prostate Cancer and its Treatment Options: 
Localized prostate cancer is defined as T1 to T2 staging with no regional or distal spread 
of disease.50 There are several curative treatment options available to treat localized PC 
including Radical Prostatectomy (RP) or Radiation Therapy (RT), with or without 
Androgen Deprivation Therapy (ADT).51   
 
1.7.1 Radical Prostatectomy: 
Radical prostatectomy (RP) is a surgical treatment option offered by many urologists for 
localized PC, involving the removal of the entire prostate gland and seminal vesicles, 
with the potential to involve sampling of the pelvic lymph nodes52 Through this 
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procedure, all the cancer is removed during the early stage of disease, however, there are 
also associated risks including erectile dysfunction and urinary incontinence 53 
 
1.7.2 Radiation Therapy:  
Radiation therapy (RT) is an alternative treatment to surgery involving the exposure of 
the prostate gland, seminal vesicles, and pelvic lymph nodes to high doses of ionizing 
radiation.54 RT may cause short term side effects such as urinary and rectal toxicity, and 
long term side effects as erectile dysfunction.53 
 
1.7.3 Androgen deprivation Therapy (ADT): 
Androgen Deprivation Therapy (ADT) is not a curative treatment option for PC because 
it works only as an anti-androgen to prevent further cancer growth. Accordingly, it is 
usually combined with the radiation therapy.55 It oftentimes causes anti-androgen side 
effect such as erectile dysfunction.56 
  
1.7.4 Treatment Selection: 
Usually the family physician participates in a detailed discussion with the patient 
regarding various available treatment options.48 The clinical benefit of immediate 
intervention for localized prostate cancer does not always show a clear benefit because 
PC is a slow progressing disease,57 and because such treatment may cause both short and 
long-term side effects.48 Because of this, and the fact that most patients will not die from 
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PC, the guidelines in United States recommend sharing the decision making between the 
patient and physician to either be treated or to be observed (active surveillance).46  
 
1.8 Active Surveillance: 
Active surveillance is a management approach that is being more widely adopted to avoid 
potential complications that result from over-diagnosis and over-treatment.14 It is an 
observational follow-up approach that delays immediate intervention in patients with PC 
who are considered to be at low risk  for developing clinically significant  disease.57  
 
Over-diagnosed cancer is defined as the early detection of clinically insignificant cancer 
with screening that may not have been discovered nor diagnosed without the use of 
screening, thereby potentially resulting in over-treatement.58,58 Over-treatment is defined 
as an intervention that lacks benefit and might also lead to unnecessary harm and cost to 
the patient.59  
 
Yearly, more than 100,000 men are diagnosed with low-grade PC who may qualify for 
management by active surveillance.41 The mortality rate for management by active 
surveillance is small, currently estimated at 3% at 10 years.60 For most patients with a 
low risk cancer (Gleason score sums ≤ 6), the lead time from diagnosis until clinical 
progression is quite long.61 Data from several centers suggest that the intervention after 
disease progression does not affect the opportunity to cure of the disease.60   
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The percentage of men diagnosed with localized PC who might be managed by active 
surveillance has risen yearly, increasing from approximately 25% in the 1990s to 50% in 
2007.62 However, the percentage of men managed with active surveillance has remained 
the same for the last decade,63 as the majority of these men are treated with either 
surgery, radiation or hormonal therapy.16 Potential explanations for this include: patients 
preferring an intervention over surveillance, urologists preferring either surgery or 
radiation therapy, and, oncologists preferring radiotherapy.64 
 
1.8.1 Strategies: Active Surveillance versus Watchful Waiting:  
Active surveillance is different from the “watchful waiting” strategy. Active surveillance 
is considered curative in intent while the “watchful waiting” strategy is considered 
palliative management to the elderly who have significant comorbidity. Also, active 
surveillance is a more structured program following up with the patients with PC for any 
sign of disease progression, and allowing for immediate intervention when there is any 
sign of disease progression.48  
 
1.8.2 Criteria for Active Surveillance: 
The criterion for managing a patient with PC by active surveillance involves the 
consideration of both clinical data and biopsy results. It is important to note that there are 
no universally accepted standards for defining the exact criteria to offer active 
surveillance to a patient with PC. Rather each center tends to use its own criteria (Table 
4).60 For example, Johns Hopkins hospital restricts active surveillance to patients with a 
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very low risk of disease whose biopsies show a Gleason score sum of (3+3) cancer on 
only one side of the prostate gland (stage T1).  If and when subsequent biopsies 
demonstrate higher levels of risk, the patient will be treated.65 
 
Alternatively, the University of California, San Francisco (UCSF) has a bit more liberal 
criteria, allowing patients with “low risk” as well as “very low risk” disease to qualify for 
active surveillance. Unlike the standards used by Johns Hopkins, a stage T2 cancer would 
qualify for active surveillance according to UCSF criteria.66 
 
Some centers will consider patients with Gleason score sum of 7 (3+4) prostate cancer, 
and also patients with PSA levels ≤ 15 ng/ml for active surveillance.67 Other centers only 
offer active surveillance to patients with Gleason scores of 7 (3+4) who are older than 70 
years of age.65 
Table 4: Criteria of Active Surveillance in Some Institutions.67 
Name of 
center 
Clinical 
stage 
PSA 
(ng/ml) 
Biopsy 
Gleason 
score 
Number of 
+ve cores 
% of 
cancer in 
single core 
John 
Hopkins 
T1c -* ≤6 ≤2 ≤50 
 University 
of  Toronto 
 T1c-T2a ≤10 ≤6 - - 
UCSF 
 
 
T1-T2  ≤10 ≤6 ≤1/3 total 
cores 
≤50 
 
Royal 
Marsden 
T1-T2 ≤15 ≤3+4 ≤50% all 
cores 
- 
* Johns Hopkins use PSA density (PSA level/ prostate size) <0.15 ng/ml. 
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Abbreviation: UCSF= University of California, San Francisco. 
Johns Hopkins in Maryland. University of Toronto in Canada. Royal Marsden in United 
Kingdom.  
 
 
The most common criteria for offering active surveillance (Table 5) include a PSA level 
≤10 ng/ml, the clinical stage of disease as T1 to T2a, a Gleason grade ≤6, and the extent 
of cancer in any biopsy core <50%.68 If the patient is older than 70, the criteria may be 
extended to include PSA ≤15ng/ml, and/or a Gleason grade of 3+4.69 
 
Table 5: Common Criteria for Active Surveillance.68 
PSA level  10 ng/ml 
Cancer stage T1-T2a 
Gleason score ≤6 
% of cancer in each core ≤50% 
Number of core positive 2 or less 
 
1.8.3 Follow-up Protocol during Active Surveillance:   
Even if the risk of progression of the disease in low-grade PC is small, patients assigned 
to active surveillance are monitored closely.60 The purpose of close monitoring during 
active surveillance is to be able to detect disease progression if and when it occurs. The 
type of monitoring involved, just as is the case with the specific criterion for qualifying 
for active surveillance, is institution-dependent. The follow-up assessments include PSA 
measurement, rectal examination, and prostate biopsy (Table 6).41, 68 
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Table 6: Follow-up Protocol during Active Surveillance in Some Institutions. 70 
Institution PSA Digital rectal 
examination 
Prostate biopsy 
Johns Hopkins Every 6 months Every 6 months Yearly 
University of 
Toronto 
Every 3 months/ 1st 
year, then every 6 
months. 
- 1st biopsy within 6-12 
months, the yearly 
until age of 80 years. 
UCSF 
 
 
Every 3 months. Every 3 months 1-2- year interval. 
Royal Marsden 3-6 months 3-6 months - 
Abbreviation: UCSF= University of California, San Francisco. 
 
1.8.4 Signs for Intervention during Active Surveillance: 
Patients involved in active surveillance may be offered a curative intervention at any 
time, particularly if signs of disease progression are evident. Signs of disease progression 
may include: a doubling of the blood PSA level in less than 3 years; an increase in the 
Gleason score in the subsequent biopsy; or an increase in the percentage of tumor in the 
biopsy.41 Some studies suggest that the delay of treatment during active surveillance does 
not interfere or delay the chance of cure.69 On average, up to 33% of patients under active 
surveillance receive further treatment after 2.5 years of surveillance.71 
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1.9. Study Rational and Previous Studies: 
The success of active surveillance depends on the accurate identification of low risk PC 
during the screening process.72 Despite improvements in the methods used to obtain 
biopsies, many cancers of the prostate are still missed. Many studies have demonstrated 
that patients can have high-grade cancer that is undiagnosed by TRUS biopsy.73,74  
 
 The accurate diagnosis of prostate cancer grade and stage will help in the widespread 
acceptance of active surveillance.63 Definitive accuracy of prostate biopsy can be 
ascertained with surgical removal of the whole prostate (radical prostatectomy) and the 
histological examination of the entire specimen.36  
 
 Gleason score is the most reliable factor for identifying the biological potential of 
prostate cancer.75 Therefore, the optimal management of patients with PC depends on the 
accurate assignment of the Gleason score at the time of disease diagnosis with prostate 
biopsy.76 However, the Gleason score assignment is sometimes not the same between 
prostate biopsy and radical prostatectomy. The Gleason score assigned after radical 
prostatectomy may be higher (up-graded) or, more rarely, lower (down-graded) compared 
to prostate biopsy Gleason score.76,77   
 
Discrepancies in the assignment of Gleason score following a biopsy versus radical 
prostatectomy can be explained by factors including pathology error or disagreement, 
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borderline cases, or by sampling error, with sampling error being the most common 
reason. 78  
 
Pathology error may result from the inexperience of the pathologist who reads the biopsy. 
It should be noted that the Gleason score of a biopsy is sometimes subject to change 
when it is read by a genitourinary specialist.  The upgrade in Gleason score results in a 
change in the management in 10% of patients.79  
 
In borderline cases where the tumor has features that fall between 2 Gleason grades, each 
pathologist might grade it differently. Sampling error occurs when the tumor obtained by 
biopsy is not reflective of the tumor in the prostate. This is the most common cause of 
incorrect Gleason grading as described by most researchers.76  
 
Diagnostic prostate biopsy requires only small amounts of prostate tissue in relation to 
the total prostate size (Figure 3). As PC is heterogeneous and multifocal in nature, it 
might be easy to miss a small volume of high-grade cancer resulting in the under-grading 
of a patient’s cancer, or less commonly, to miss a large area of a lower grade cancer 
resulting in the over-grading of that cancer.76 Single Gleason grade PC is only seen in 10-
33% of all patients.80 
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Figure 3: Prostate Biopsy Core (pointed to by the pen). 
(From Dr. Gaston library. Permission was granted) 
 
As mentioned previously, sampling error can be  reduced by taking more biopsy cores, 
however, the accuracy of the biopsy will still be limited by sampling error  if the tumor is 
relatively small.77 Similarly, cancer detection is more difficult with a large sized prostate, 
especially for low volume cancers.81 An association between higher cancer detection 
rates with small prostate volumes have been found.82,83    
 
To avoid the under-sampling of a large prostate gland, more biopsy cores can be taken to 
more adequately sample a greater proportion of the prostatic tissue.81 However, while 
increasing biopsy cores in a large size prostate helps to avoid under-sampling, the cancer 
detection rate does not exceed 26%.84 In order to decrease the potential for sampling 
error, some urologists recommend that the number of biopsy cores taken should depend 
upon the prostate volume. However at most centers, 12 core biopsy schemes involving a 
systematic sampling of the prostate gland are the current standard of care.85  
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The prostate biopsy sampling pattern differs somewhat between centers, and some studies 
suggest increasing the number of biopsies taken from the transitional and anterior 
prostatic zones as this can improve the cancer detection rate from 20.4% to 41%.83  Up to 
60% of patients whose biopsies are assigned a Gleason score of 6 (low-grade cancer) are 
up-graded after radical prostatectomy.78,86,87 Conversely, only 25% of biopsies are  down-
graded following radical prostatectomy.88  
 
A radical prostatectomy is a surgical procedure different from the TRUS biopsy that 
involves the removal of the entire prostatic gland. The specimen is examined 
microscopically from which the final Gleason score assigned.89  
 
Consequently, the Gleason score from pathology reports following radical prostatectomy 
is sometimes different from the Gleason score following a TRUS- biopsy. This discord of 
Gleason score assignment may result in the incorrect assessment of the cancer’s 
aggressiveness and prognosis, which in turn may result in improper treatment.90 
 
There are many predictive variables for Gleason score up-grading following radical 
prostatectomy, including: prostate volume, the number of core biopsies taken, and the 
number of cancers found in the biopsy cores.91 
 
If the Gleason score is ≤6 at the time of diagnostic biopsy, the potential for up-grading is 
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significantly associated with a prostate volume <34.5 cc.39 When the number of core 
biopsies are > 12, there is a greatly likelihood for a correct diagnosis and the risk of 
upgrading is thereby reduced.92 Conversely, when there are more cores with cancer, the 
risk of up-grading is higher.93 
 
1.10.1 Study Purpose: 
Low use of active surveillance by urologists might be due to the inability to accurately 
assess the grade and stage of the prostate cancer.94 Therefore, as the capability improves 
to accurately assess and assign PC to the appropriate grade and stage, it is hoped that 
active surveillance will gain more widespread acceptance,5 and thereby over-treatment 
will decrease.63 
 
The ability to accurately assign a Gleason score following prostate biopsy is fundamental 
to assigning patients with low-grade prostate cancer to active surveillance. Thus, the 
purpose of this study was to determine the accuracy of the prostate biopsy to assign 
accurate Gleason score and cancer stage in comparison with the Gleason score and cancer 
stage assigned after radical prostatectomy in adult prostate cancer patients treated at Tufts 
Medical Center. Farther, to determine whether the prostate biopsy is a sufficiently 
diagnostic procedure to offer active surveillance in patients with low-grade PC (GS ≤6) 
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1.10.2 Study Question:  
1- Is the Gleason score after prostate biopsy concordant with Gleason score after radical 
prostatectomy?  
2- Is the Gleason score after prostate biopsy versus radical prostatectomy accurate and 
appropriate for offering patients active surveillance?   
 
1.10.3 Study objectives: 
Primary Objectives:    
For all patients who had both biopsy and radical prostatectomy pathological reports, the following 
objectives will be assessed: 
1) Measurement of the degree of agreement between biopsy Gleason score and 
prostatectomy Gleason score.  
2) Measurement of the sensitivity and specificity of prostate biopsy to predict 
prostatectomy Gleason score in the PC patients treated at Tufts Medical Center.  
3)  Evaluate the concordance (have same cancer stage) and discordance (have 
different cancer stage) between biopsy and prostatectomy cancer stage. 
Secondary Objective:   
For the patients who were eligible for active surveillance (Gleason score 6).  
1- Measurement the sensitivity, specificity, positive predictive value and negative 
predictive value of prostate biopsy Gleason score in comparison with prostatectomy 
Gleason score.  
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2- Evaluate whether the use of specific criteria to offer active surveillance can reduce 
the risk of up-grading. 
1.10.4 Endpoints/Outcomes of Interest: 
1- Primary endpoint: Gleason score following PC biopsy as compared to Gleason score 
following radical prostatectomy. 
 
2- Secondary endpoint: Cancer stage following prostate cancer biopsy as compared to 
cancer stage following radical prostatectomy. 
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METHODS AND MATERIALS  
 
 
A retrospective cohort study was conducted at Tufts Medical Center (TMC) using data 
from the anatomic pathology clinical database (CoPath) in the Department of pathology. 
Data from patients who underwent either prostate biopsy or radical prostatectomy 
between 2007 and 2010 were included in the analysis for this study. This database was 
accessible to Tufts investigators through the Tufts Medical Center intranet. This database 
was HIPAA-compliant (including only de-identified case descriptions for analyses). 
 
 All prostate biopsies included in this study were identified by specimen numbers and 
included information about pathological variables including the: total number of biopsy 
cores obtained; biopsy Gleason score (GS); number of biopsy cores positive for cancer; 
maximum percentage of cancer in each core, and any other pathological features such as 
atypia or high-grade intra-epithelial neoplasia.  
 
From the same database, pathological information about radical prostatectomy was also 
collected including the: prostate weight and size; percentage of tumor in the gland; tumor 
peri-neural invasion; presence of positive margins; tumor extra-prostatic extension; 
lymph node invasion; and, prostatectomy Gleason score patterns and sums. 
 
 From the Tufts Clinical and Translational Science Institute, study subject code numbers 
(CNs) were obtained so that the same subject biopsies and radical prostatectomy results 
could be compared.   
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Using the study subject CNs, prostate biopsy and radical prostatectomy information for 
each patient was identified and matched. The GS and cancer stage from the radical 
prostatectomy and the biopsy reports were compared.  
 
The Gleason scores following radical prostatectomy were examined based on upgrading, 
downgrading, or GSs that remained unchanged. Subjects were categorized into the 
following groups according to biopsy and radical prostatectomy Gleason scores sums: 
low, moderate, and high-grade (Table 7). Note that a Gleason sum of 7 may indicate that 
the predominant pattern is a low-grade 3 (3+4 cancer) or an intermediate pattern 4 (4+3 
cancer). Using biopsy and radical prostatectomy GS sums, the number and percentage of 
patients who upgraded, downgraded, or remained the same according to the similarity in 
GS sums between biopsy and radical prostatectomy were assessed.  
 
Table 7: Gleason Score Sums Using in the Study Analysis. 
         Gleason pattern                                            Gleason sums 
Low-grade  3 6 
Moderate-grade 4 7 
High-grade 5 8 or more 
 
The cancer stage following radical prostatectomy and biopsy report was also evaluated 
for concordance (same cancer stage) or discordance (different cancer stage) for each 
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subject. The number and percentage of concordance and discordance in cancer stage were 
calculated. 
 
In cases where the study subject had more than one biopsy procedure (one without cancer 
and another with cancer), the final cancer positive biopsy procedure was used to compare 
with the GS sums to radical prostatectomy.  Also, it should be noted that each biopsy had 
multiple cores and the cores may have had different GS sums, in which case the core with 
the highest GS sum was used for the comparison. Subjects with no biopsy or radical 
prostatectomy pathological reports (unmatched subjects) were excluded from the 
analysis.  
 
  Upgrading was defined based on the following criterion:  
1- If the GS sums in radical prostatectomy was higher than biopsy GS sums. 
2- If the appearance of the tertiary grade in radical prostatectomy was higher than 
the primary and secondary biopsy GS sums (e.g. GS 6 (3+3) to GS 6 (3+3 tertiary 
4)). 
3- If there was a change in the primary and secondary pattern to a higher GS (e.g. 
GS 7 (3+4) to GS 7 (4+3)).  
Conversely, downgrading was defined as any decrease in GS sums following radical 
prostatectomy compared to biopsy GS sums as noted above. 
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To assess whether the use of specific criteria to offer active surveillance (strict criteria or 
broad criteria) in the subjects with low-grade PC (GS 6) will reduce the risk of up-
grading. This was evaluated in two steps: 
 
1- The percentage of GS upgrading for low-grade PC (GS 6) was calculated for 
potentially eligible patients for active surveillance according to the Johns Hopkins criteria 
(strict criteria). 
 
Inclusion criteria: 
1. Gleason score ≤ 6 (3+3). 
2. Number of cancers positive cores  ≤ 2 
3. % of cancer in a single core <50 
4. Tumor stage T1c. 
Exclusion criteria: 
1. Gleason score > 6 (3+3). 
2. Number of cancers positive cores >2. 
3. % of cancer in a single core >50. 
4. Tumor stage T2 or above. 
 
2- The percentage of GS upgrading for low-grade PC (GS 6) was calculated for 
potentially eligible patients for active surveillance according to the UCSF criteria (broad 
criteria). 
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Inclusion criteria: 
1. Gleason score ≤ 6 (3+3). 
2. Number of cancers positive cores ≤ 1/3 
of total cores. 
3. % of cancer in single core <50. 
4. Tumor stage ≤ T2. 
Exclusion criteria: 
1. Gleason score > 6 (3+3). 
2. Number of cancers positive cores > 
1/3 of total cores. 
3. % of cancer in single core >50. 
4. Tumor stage above T2 
 
 Statistical Analysis: 
The accuracy of the prostate biopsy for each paired specimen with radical prostatectomy 
GS sums and the degree of agreement was calculated by weighted kappa statistics. Then 
the sensitivity (SE) and specificity (SP) were measured for each GS sums with the ROC 
curve.  
 
 The concordance (had same cancer stage) and discordance (had different cancer stage) in 
the cancer stage of paired prostate biopsy and radical prostatectomy was evaluated and 
statistical significant of discordance was calculated by the McNemar’s test.  
 
 The accuracy of prostate biopsy Gleason score to predict the prostatectomy Gleason 
score for low-grade prostate cancer (GS 6 (3+3)) (potentially eligible for active 
surveillance) was evaluated by calculating the sensitivity (SE), specificity (SP), positive 
predictive value (PPV), and negative predictive value (NPV)  
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 Chi square tests were used to evaluate whether the use of specific criteria (Johns 
Hopkins or UCSF) to offer active surveillance to the subjects with the low-grade PC (GS 
6) will significantly reduce the risk of up-grading among this cohort. 
 
The Chi square test was used to assess the association between upgrading with the 
following pathological categorical variables, including: the number of cores taking (≥12 
or ≤12 cores), cancer stage, surgical margin, and the presence of extra prostatic extension 
of the cancer after radical prostatectomy. The Wilcoxon-test was used to assess the 
association between upgrading with the following continuous variables including: 
subjects’ age, number of biopsy cores positive for cancer, percentage of prostate tissue 
involved with cancer, and prostate weight. For all tests, the statistical significant was set 
at the point of 0.05. 
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RESULTS 
 
 
3.1 Summary of Pathological Characters of Study Population: 
 
From 2007- 2010, a total of 652 prostate biopsies were performed at TMC. Out of the 
652 prostate biopsies (PB) performed, 232 (36%) had PC as the final diagnosis. During 
this same time, a total 115 radical prostatectomies (RP) were performed. Of the 115 
radical prostatectomies, 83 (72%) were matched to the respective prostate biopsies 
(Figures 4 and 5).    
 
 
 
Figure 4: Prostate Biopsy (PB) and Radical Prostatectomy (RP) Study Cohorts. 
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Figure 5: Distribution of matched prostate biopsy. 
 
The pathological characteristics of the prostate biopsies are presented in Table 8. For all 
of the 232 biopsied subjects diagnosed with cancer, 121 (52%) had a GS 6. The mean 
number of cores taken was 11 and the mean number of cancer positive cores was 3.4. The 
pathological characteristics and distribution of radical prostatectomies are presented in 
Table 9. Of all subjects who had radical prostatectomy, 63 (55%) had a GS 7. The mean 
subject age was 62 years old. The mean prostate weight was 51 gm, and the mean 
percentage of prostate tissue involved with cancer was 20.4% of the gland size. Positive 
margins with tumor were found in 53 subjects (46%), and cancer stage 2 was found in 96 
subjects (83%). Lastly, extra-prostatic extension at the time of radical prostatectomy was 
found in 14 subjects (12%). 
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Table 8: Prostate Biopsies Pathological Summary.  
Pathological characteristics Prostate biopsy 
Total number of subjects (n, %)   
         subjects without cancer 420 (64) 
         subjects with Cancer 232 (36) 
For subjects with cancer positive (n, %) 
Gleason score (n, %)    
          6 (3+3) 121 (52) 
          7 (3+4) 47 (20) 
          7 (4+3) 27 (12) 
          8 -10 37 (16) 
  
Cancer positive matched specimens  83 (36) 
Mean of number of biopsy cores taken 11 
Mean number of cancer positive cores       3.4 
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Table 9: Radical Prostatectomy Pathological Summary. 
Pathological characteristics Radical prostatectomy 
Total number of subjects (n, %) 115 (100) 
 Gleason score (n, %)   
          6 (3+3)                   38 (33) 
          7 (3+4)   43 (37.5) 
          7 (4+3)   20 (17.5) 
          8 -10 14 (12) 
  
Matched cases (n, %) 83 (72) 
Subjects age in year (n, %)   
           <50    4 (3.4) 
            50-59 38 (33) 
            60-69 61 (53) 
            70-79    12 (10.4) 
Mean prostatic weight (gm)                    51 
Mean of % of prostate tissue involve 
with cancer 
                   20.4 
Pathological stage (n, %)   
         PT2 96 (83) 
         PT3 19 (17) 
Margin status n/total 
        Positive margin overall        53/115 (46) 
        Positive margin in PT2     40/96 (42) 
        Positive margin in PT3     13/19 (68) 
Extra prostatic extension* (n, %)   
       No extra prostatic extension                   101 (88) 
       Positive extra prostatic extension 14 (12) 
*extra prostatic extension: cancer spread outside of prostate included seminal vesicle 
invasion.  
 
 
 
3.2 Comparison of all Prostate Biopsy and Radical Prostatectomy Gleason Scores: 
As presented previously (Table 7), specimens (from both biopsy and radical 
prostatectomy) were categorized into the following Gleason grades: low (Gleason sum 
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score 6), moderate (Gleason sum score 7), and high (Gleason sum score 8-10). A 
comparison of the distribution of GS sums in the biopsies and radical prostatectomies is 
presented in Table 10 and Figure 6, respectively. A GS of 6 was assigned the most in 
prostate biopsies (52%) compared to 33% in the prostatectomy. Conversely, more 
prostatectomies (55%) were rated with a GS of 7 compared to 32% in prostate biopsies 
(Figure 7). There was a clear difference in the distribution of GS sums in biopsies 
compared to radical prostatectomies, with a more than doubling in the number of low-
grade (GS, 6) and high-grade (GS, 8-10) GS in the biopsies compared to radical 
prostatectomies.      
 
Table 10: The Distribution of the GS sums in Biopsy and Radical Prostatectomy. 
GS Prostate Biopsy n (%) Radical Prostatectomy n (%) 
GS 6 121 (52) 38 (33) 
GS 7 74 (32) 63 (55) 
GS 8-10 37 (16) 14 (12) 
Total  232 115 
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Figure 6: Comparison of the Distribution of GS sums in Biopsy and Radical Prostatectomy. 
 
 
 
Figure 7: Comparison of the Percentage of GS sums in Biopsy and Radical Prostatectomy. 
 
3.3 Results of Matched Biopsy and Radical Prostatectomy Gleason Scores: 
Table 11 illustrates the results of matched prostate biopsy and radical prostatectomy 
Gleason scores. In this instance, specimens assigned a GS of 7 in both the biopsy and 
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radical prostatectomy cohorts were spliced into GS 7(3+4) and GS 7(4+3) to correctly 
account for the up-grading and down-grading between those two groups; the GS 7 (4+3) 
is considered a more aggressive tumor than the GS 7 (3+4). 
 
Table 11 and Figure 8 illustrate the results of the matched prostate biopsy and radical 
prostatectomy Gleason scores. Overall the biopsy GS accurately predicted the 
prostatectomy GS in 46%, was upgraded in 38% of the time, and was down-graded 16% 
of the time using the radical prostatectomy specimen compared to the prostate biopsy 
specimen. Up-grading occurred in 50% of prostate biopsies with a GS of 6, and in 28% of 
biopsies with a GS of 7. Down-grading occurred in 31% and 78% of prostate biopsies 
with a GS of 7 and a GS of 8-10, respectively.  
 
Table 11: Matched Prostate Biopsy and Radical Prostatectomy Gleason Score. 
 
Prostate 
Biopsy 
Radical Prostatectomy n (% of biopsy GS) Total n (%) 
GS 6 GS 7 (3+4) GS 7 (4+3) GS 8-10 
GS 6 
(3+3) 
24 (50) 16 (33) 6 (13)     2 (4) 48 (59) 
GS 7 
(3+4) 
3 (17.6) 8 (47) 3 (17.6)  3 (17.6) 17 (20) 
GS 7 
(4+3) 
1 (8) 5 (42) 4 (33)     2 (17) 12 (14) 
GS 8-10 0 (0) 1 (17) 3 (50)     2 (33)* 6 (7) 
Total 28 (34) 30 (36) 16 (19) 9 (11) 83 
*one of the specimen was up-graded. 
 
  
39 
 
Figure 8: Biopsy GS Up-graded, Down-graded, or Remained the same on RP. 
 
The degree of agreement between the biopsy and radical prostatectomy Gleason scores 
was assessed by calculating of weighted kappa (kappa = 0.33) with a 95% confidence 
interval of 0.19- 0.47, indicating fair agreement between the biopsy and radical 
prostatectomy Gleason score. 
 
3.4 Sensitivity and Specificity of Prostate Biopsy Gleason scores: 
The sensitivity and specificity of the prostate biopsy to predict the low, moderate, and 
high prostatectomy GSs were evaluated using the ROC curve and are presented in Table 
12. Both the curve and Table 12 showed that the sensitivity of prostate biopsy to predict 
prostatectomy GS decreased with the increasing in biopsy Gleason score (86%, 26%, 
25%, and 22%) for GS 6, GS 7 (3+4), GS 7 (4+3), and GS 8-10 respectively. While the 
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specificity of the prostate biopsy (to exclude the GS that was excluded by prostatectomy) 
increased with increasing prostate biopsy Gleason scores (56%, 85%, 88%, and 95%) for 
GS 6, GS 7 (3+4), GS 7 (4+3), and GS 8-10 respectively (Table 12 and Figure 9).  
 
Table 12: Sensitivity and Specificity of Biopsy at 4 different Gleason Scores. 
Gleason score Sensitivity Specificity 
GS 6 (3+3) 86% 56% 
GS 7 (3+4) 26% 85% 
GS 7 (4+3) 25% 88% 
GS 8-10 22% 95% 
 
Figure 9: ROC Curve of the biopsy at 4 Different Gleason Scores. 
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 3.5 Results of Matched Biopsy and Radical Prostatectomy Cancer Stage: 
Prostate biopsy and radical prostatectomy cancer stages were matched in 78 (94%) 
specimens (5 biopsies had missed cancer stages).  Results showed concordance (both 
biopsy and prostatectomy had the same cancer stage) in 46 (59%) and discordance (had 
different cancer stage) in 32 (41%) specimens (Table 13). The discordance between 
biopsy and radical prostatectomy cancer stages was evaluated with the McNemar’s test. 
The discordance between biopsy and prostatectomy cancer stage was statistically 
significant (P value < 0.0001).  
 
Table 13: Matched Biopsy and Radical Prostatectomy Cancer Stage. 
Prostate biopsy Radical prostatectomy   
T2a-T2b 
(unilateral) 
T2c- T3 
(bilateral) 
Row Total 
Unilateral 21 31 52 
26.92 39.74 66.67 
Bilateral 1 25 26 
1.28 32.05 33.33 
Column Total 22 56 78 
28.21 71.79 100 
 
3.6 The Sensitivity and Specificity of Prostate Biopsy for Low-Grade PC (GS 6) 
(eligible for active surveillance): 
In prostate biopsy specimens with a low-grade GS (GS 6), up-grading occurred in 50% of 
cases. These cases were upgraded primarily to a GS of 7 (46%). The sensitivity 
(SE),specificity (SP), positive predictive value (PPV), negative predictive value (NPV) of 
the prostate biopsy for low-grade PC (GS 6) are shown in Table 14 and demonstrate that 
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the prostate biopsy was more sensitive (86% CI 73- 99) and less specific (56% CI 43-69) 
to predict the prostatectomy in low-grade PC (GS 6). The probability that subjects with a 
positive GS 6 test truly have the disease (PPV) was 50% while the probability that 
subjects with a negative GS 6 test truly don't have the disease (NPV) was 89%. 
 
Table 14: Low-Grade PC (GS 6).  
 
Prostate biopsy Radical Prostatectomy SE SP PPV NPV 
  GS 6 Higher than  GS 6  
 
86  
 
 
 56 
 
 
50  
 
 
89  
 GS 6 24 24 
Higher than GS 6 4 31 
    
  
3.7.1 Results of Eligible Patients for Active Surveillance (AS) according to Johns 
Hopkins (JH) Criteria: 
Of the 232 prostate biopsies diagnosed with PC, 68 (29%) were eligible for AS according 
to JH criteria. Of the 68 cases eligible for AS by JH criteria, 25 subjects had biopsy   
specimens matched to radical prostatectomy specimens. Of the total matched specimens 
eligible for AS according to JH criteria, 40% were upgraded, with 36% and 4% upgraded 
to moderate (GS 7) and high (GS 8-10) GS grades, respectively. (Table 15) 
 
3.7.2 Results of Eligible Patients for Active Surveillance (AS) according to UCSF 
Criteria: 
 As the UCSF criteria are broader than the JH criteria, 94 (41%) specimens were deemed 
eligible for AS according to UCSF criteria. Of the 94 cases eligible for AS by UCSF 
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criteria, 37 subjects had prostate biopsies matched to radical prostatectomies. Of the total 
matched specimens eligible for AS (according to UCSF criteria), 41% were upgraded, 
with 38% and 3% upgraded to moderate (GS 7) and high (GS 8-10) GS grades, 
respectively. 
  
 If all the specimens with low-grade PC (GS 6) were included in active surveillance 
without the use of any additional criteria, up-grading would occur in 50%. When the 
criteria for active surveillance was used to offer active surveillance with low-grade PC 
(GS 6) by both Johns Hopkins and UCSF criteria, upgrading would have occurred in 40% 
and 41% of cases, respectively (Table 15)  
 
Table 15: Summary of all Low-Grade PB results, those Eligible for AS according to 
JH and according to UCSF Criteria. 
 
Prostate biopsy GS 6 Radical prostatectomy Total n (%) 
GS 6 (%) GS 7 (%) GS 8-10(%) 
All GS 6 in biopsy 24 (50) 22 (46) 2 (4) 48 (100) 
     
Eligible by JH criteria 15 (60) 9 (36) 1 (4) 25 (52) 
     
Eligible by UCSF criteria   22 (59) 14 (38) 1 (3)  37 (77) 
     
 
3.7.3 Eligible and Non-eligible Subjects for AS according to JH criteria:  
Of the matched specimens with low-grade PC (GS 6), and based on the JH criteria, 25 
(52%) with low-grade PC would be eligible for active surveillance, with up-grading 
occurring in 40% compared to 50% in the prostate biopsies with a GS of 6 (without the 
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use of additional criteria). The Chi square was used to assess whether the use of JH 
criteria to offer AS to the patient with low-grade PC (GS6) may significantly reduce the 
risk of up-grading (compared to no additional  criteria) (Table 16). This difference was 
not statistically significant.  
 
Table 16: Eligible and Non-eligible Subjects for AS by (restrict) JH Criteria. 
 
Biopsy GS 6  
Prostatectomy GS 6  
Total remained same up-graded 
Eligible by JH 15 10 25 
Non eligible by JH 9 14 23 
Total 24 24 48 
 
4.7.4 Eligible and Non- eligible Subjects for AS according to UCSF Criteria:  
Of the matched specimens with low-grade PC (GS6), and based on the broader (UCSF) 
criteria, 37 (71%) specimens with low-grade PC (GS 6) would be eligible for active 
surveillance. Of these cases, up-grading would have occurred in 41% compared to 50% 
of all biopsies with score of GS 6 (without the use of any criteria). The Chi square was 
used to assess whether the use of UCSF criteria to offer AS to the patient with low-grade 
PC (GS6) may significantly reduce the risk of up-grading (compared to no use of any 
criteria) (Table 17). This difference showed a statistically significant difference in 
reducing the risk of up-grading with the using of UCSF criteria compared to no use of 
any criteria (a P value of 0.026).  
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Table 17: Eligible and Non-eligible Subjects for AS by (broader) UCSF Criteria. 
 
Biopsy GS 6 
Prostatectomy GS 6  
Total remained same up-graded 
Eligible by UCSF 22 15 37 
Non eligible by UCSF 2 9 11 
Total 24 24 48 
 
3.8 Association between Up-graded and different pathological variables in Biopsy 
and Radical Prostatectomy Pathological Reports:  
The evaluation of association between different pathological variables with the up-graded 
group compared to the remained same are presented in Table 18. Comparing the number 
of cores taken between the up-graded and the remained same groups, the up-graded group 
had a significantly lower number of cores taken compared to the remained same group (P 
value = 0.03). Comparing the positive surgical margins for cancer between the up-graded 
and the remained same groups, the up-graded group had more cases with positive surgical 
margins (53%) compared to remained same group (35%). However, the difference was 
not statistically significant (P value = 0.11). The remaining pathological variables were 
similar between the two groups (up-graded VS. remained same) and did not showed any 
statistically significant difference. 
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Table 18: The Pathological Impact of Changes in GS.   
Pathology Category Upgraded Same P 
Number of Patients 
 
-- 31 39 -- 
Categorical Variables     
Cores taken 
 
 
>12 24(80%) 38(97.4%) 0.03 
<12 6(20%) 1(2.6%) 
Stage of cancer 
 
 
Stage2 25(80.6%) 33(84.6%) 0.66 
Stage3 6(19.4%) 6(15.4%) 
surgical margins Not 
involved 
14(45.2%) 25(64.1%) 0.11 
 
 
involved 17(53.8%) 14(35.9%) 
Extra prostate 
extension 
 
non 27(87%) 34(87.2%) 0.99 
present 4(13%) 5(12.8%) 
Continuous Variables 
Age , mean 
 
 62.484 61.919 0.71 
Number of cores 
Invaded with cancer, 
mean+std 
 
-- 2.93+2.27 2.95+2.41 0.97 
Prostate weight, 
median, gm 
 
-- 43 42 0.78 
Percent of cancer in 
prostate, median 
-- 10 10 0.97 
Abbreviation: std = standard deviation. 
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DISCUSSION 
 
 
The Gleason score (GS) is an essential factor in the prognosis of PC and plays an 
important role in treatment decisions.95,96 It also shows some correlation with mortality 
rates, time of recurrence of prostate cancer after treatment, and response to the 
treatment.97 A score of 6 is the most common GS finding, either during the autopsy or 
during the screening process for PC, and men with a pure Gleason score of 6 (no other 
higher Gleason score) at the time of the PC diagnosis rarely exhibit the potential for 
disease progression or metastasis.98 
 
Accordingly, PCs with a Gleason score of 6 are good candidates for active surveillance. 
However, prior to offering active surveillance to these patients, it is important to evaluate 
the accuracy of the Gleason scoring system from biopsy specimens. This study was 
planned to analyze TMC’s ability to predict the prostatectomy Gleason score. 
 
In the current study, the distribution of prostate biopsy Gleason scores (GS 6, GS 7, GS 
8–10) differed from the distribution of prostatectomy Gleason scores PC (GS 6, GS 7, GS 
8–10). A GS of 6 was the most common Gleason score among biopsy specimens (52%); 
this result was expected in the United States due to the wide use of screening.97 
Meanwhile, a GS of 7 was the most common Gleason score among the prostatectomy 
specimens (55%); a result similar to Takahashi and Epstein’s results in 2013.99  
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 The findings from the current study demonstrated the inaccuracy of the biopsy Gleason 
score (all Gleason grades) in predicting the prostatectomy Gleason score. The biopsy 
Gleason score had an overall accuracy of 46%, with upgrading occurring in 38% of cases 
and downgrading occurring in 16% of cases. These results were comparable to those 
from a previous study showing that the prostatectomy Gleason score was accurately 
predicted in 55% of patients.100  
   
The study demonstrated that low (GS 6), moderate (GS 7), and high-grade (GS 8–10) 
PCs on biopsy had varying degrees of inaccuracy for predicting the prostatectomy 
Gleason grade based on upgrading and downgrading. The upgrading was highest with 
low-grade PC (GS 6). The upgrading after a radical prostatectomy in low GS prostate 
cancer occurred in 50% of cases compared to 28% of cases in moderate-grade PC (GS 7). 
The downgrading was highest among the high-grade PC (GS 8–10) (78%). These results 
have significant consequences on the selection of appropriate treatments for patients with 
prostate cancer. When patients with low-grade PC are managed with active surveillance 
and according to this study’s results, half of those patients will really have a higher 
cancer grade than is believed and will not actually be eligible for active surveillance. 
These results are also significant for men with high-grade PC as 78% of them will really 
have a lower cancer grade; this alteration of the Gleason score could affect their 
treatment. 
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Significant differences emerged in the number of cores taken between the upgrading and 
the groups that remained the same. This result was observed in previous studies, in which 
the extra cores taken increased the diagnostic accuracy by increasing the amount of 
prostate tissue sampled during the biopsy, thereby helping to improve the diagnostic 
ability of a prostate biopsy in detecting prostate cancer as well as the concordance with 
the prostatectomy Gleason score.76,101 
 
With respect to sensitivity and specificity, the prostate biopsy was more sensitive (86%) 
and less specific (56%) for low-grade PC (GS 6) compared to high GS prostate cancer 
(SE 22%, and SP 95%). The ROC curve showed that the sensitivity of the prostate biopsy 
to predict the prostatectomy GS decreased with an increase in the GS whereas specificity 
increased with an increase in the GS. As the prostate biopsy demonstrated high sensitivity 
for low-grade PC (GS 6), this indicated that the negative result of GS 6 during the biopsy 
is useful for ruling out disease (GS 6). Conversely, the prostate biopsy demonstrated high 
specificity for high-grade PC (GS 8–10), indicating that the positive result of GS 8–10 
during the biopsy is a useful ruling in the disease (GS 8-10). These findings were 
previously proven by the study and meta-analysis conducted in Lahy Clinic Medical 
Center.102  
 
Similar to the discordance in the GS assignment between biopsy and prostatectomy, in 
41% of the cases, the cancer stage assigned following a radical prostatectomy was not 
similar to the cancer stage assigned following a biopsy. These results have important 
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implications because the cancer stage is one of the key criteria for offering active 
surveillance (Table 5). According to the study results, the biopsy showed a low cancer 
stage (unilateral) in 31 (40%) cases and seemed eligible for active surveillance, yet these 
same cases had a high cancer stage (bilateral) after the prostatectomy, thereby indicating 
that active surveillance is not a good management option to be concluded after the biopsy 
results. 
 
The disagreement between biopsy and prostatectomy in the Gleason score might stem 
from several reasons. The upgrading is simply explained by the inaccurate TRUS biopsy 
procedure. PC is known to be multifocal in origin and is poorly seen by ultrasound. In 
addition, a limited amount of tissue is taken during the TRUS biopsy with at random 
sampling of all prostatic tissue. Therefore, it is likely that the biopsy missed a focus of 
high-grade PC.75  
 
To help reduce the risk of and need for upgrading among patients with low-grade PC (GS 
6), specific criteria to offer active surveillance to this group of patients should be used. 
For example, in the current study, upgrading occurred in 40% of the patients eligible for 
active surveillance according to the Johns Hopkins (JH) criteria, and in 41% in the 
patients eligible for active surveillance according to the UCSF criteria. The use of either 
the JH or UCSF criteria has the potential to decrease the rate of upgrading in patients 
with low-grade PC. In a previous JH study, the upgrading for low-grade PC (GS 6) 
occurred in 36.3% of cases, compared to 24% in patients eligible for active 
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surveillance.74,103 The percentage of upgrading in patients eligible for active surveillance 
according to JH criteria in this study was higher than in the previous study (40% versus 
24%). This difference might be because the previous study offered active surveillance to 
patients with low-grade PC according to both pathological and clinical criteria whereas 
this study only used pathological criteria.  
   
The difference in the total number of cases that were upgraded between the JH and UCSF 
criteria was only 1% despite the broader criteria used by UCSF (they include stage T2 
and ≤ 1/3 of total cores invaded with cancer) compared to the JH criteria. These findings 
have been described in the results of a preliminary analysis conducted in JH to evaluate 
their criteria. The researchers of this analysis hypothesized that their criteria could be 
excessively strict, thereby excluding many men from active surveillance.100   
 
Limitations: 
The current study has apparent limitations. The first limitation relates to the study design 
(retrospective study), which can be affected by the different practices and experiences of 
urologists when taking the TRUS biopsy. In addition, pathologists who review patients’ 
slides and assign the GS have different practices and experiences. Therefore, the 
measurement (misclassification) bias from different practices between urologists and 
pathologists could have potentially affected the internal validity of the study.  However, 
in TMC a second opinion from specialists to assign the GS was usually reported in the 
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pathological reports. Also, the study results were comparative to the previous study in 
terms of the degree of agreement between biopsy and radical prostatectomy.103 
 
Second, as the data were collected from a pathological database, PSA, race, and family 
history were not available for the analysis. PSA is an important criterion to consider in 
offering active surveillance. Therefore, the inclusion of patients in active surveillance in 
this study depended only on pathological criteria and did not consider clinical criteria. 
This might have affected the results of the study, which included ineligible subjects 
according to clinical criteria to active surveillance. Therefore, the percentage of 
upgrading in GS for the patients eligible for active surveillance might be high compared 
to the previous study, as already described.75 
 
Finally, while every prostate cancer patient from the predefined four-year study period 
was included in this study, the number of subjects who received both procedures (biopsy 
and radical prostatectomy) was extremely limited (83 cases). This means that care should 
be taken when drawing conclusions from the analysis of these data. A larger sample 
would have been preferable as the results could be extended to make predictions about a 
broader population. 
 
The present study also has some strengths. As both the Gleason score and cancer stage 
are important factors in disease prognosis, the current study evaluated the accuracy of the 
prostate biopsy Gleason score and cancer stage to predict the radical prostatectomy 
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Gleason score and cancer stage. The study also evaluated two different criteria to offer 
active surveillance to patients with low-grade PC compared to not using any criteria, and 
the study’s findings might help to reduce the risk of upgrading in patients managed with 
active surveillance. 
 
Future directions: 
The results of this study support the need for additional investigation. A prospective 
cohort study in a similar population would be useful to allow for the collection of both 
clinical and pathological variables to offer active surveillance to the patients with low-
grade PC according to full active surveillance criteria. Also, a prospective study would be 
useful to overcome the measurement bias. For example, the prostate biopsy would be 
taken by single urologist and the cancer would be graded by single pathologist. 
Additionally, prospective study would be adequately powered and large enough to get 
more matched biopsy and radical prostatectomy cases than were observed in this 
retrospective study.  
 
 An accurate diagnosis of PC Gleason score is the first step in the choosing an appropriate 
treatment. The correct diagnosis is essential before assigning a patient to active 
surveillance (no intervention treatment). The results of this study support the limitations of 
the current diagnostic procedure. These limitations need further investigation in the future 
and must be understood by both physician and patient. Also, the future research needs to 
involve and assess the accuracy of other diagnostic techniques either by imaging 
techniques as MRI or 3D TRUS biopsy or by tumor markers (blood or tissues).  
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CONCLUSION 
 
 
The prostate biopsy Gleason score and cancer stage have a significant degree of 
limitations to predict prostatectomy Gleason score and cancer stage. Therefore, prostate 
biopsy alone is not an adequate diagnostic procedure to offer active surveillance to a 
patient with low-grade PC. At the time of determining treatment options, the physician 
must describe the significant limitation of TRUS biopsy to the patient. As inaccurate 
Gleason score at the time of diagnosis might direct the patient and physician toward a 
specific management option that would be different from ideal management options if the 
accurate Gleason score was known. 
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